Dortmund and Berlin, November 21, 2008: Scienion AG launched two new models of its successful sciFLEXARRAYER dispensing systems, the perfect tools for automated ultra-low volume liquid handling of biological samples in the genomic and proteomic world. While the small sciFLEXARRAYER DW represents the ideal entry model, sciFLEXARRAYER SX is a scalable robotic dispensing platform that can be adjusted to the needed size of the working area when ordered. Substantial customer interest in both products at recent Medica in Düsseldorf.

Invitrogen Corp. (NASDAQ: IVGN), a provider of essential life science technologies for research, production and diagnostics, today announced the launch of the first high-density microarray for the profiling of non-coding RNAs. The NCode Human and Mouse non-coding RNA microarrays consist of both non-coding RNA and messenger RNA (mRNA) content on the same array. The arrays are designed by Invitrogen and then manufactured by Agilent Technologies Inc. (NYSE: A), a technology leader in communications, electronics, life sciences and chemical analysis, using the company’s proprietary SurePrint technology.

In a campaign to significantly reduce the most common cancer affecting Mexican women, the Mexican Public Health Agency (Secretaria de Salud or SSA) has announced it is launching the first phase of a program that will offer testing for human papillomavirus (HPV), the primary cause of cervical cancer, to low-income women age 35-65. The cost of the testing will be covered by the agency. In the first phase of the screening program, which is beginning this month, more than 200,000 women in the lowest-income 125 counties are being offered the papillomavirus test along with the traditional Pap smear. In 2009, the pilot program will be expanded to include another 600,000 women in the 20 states with the highest death rate from cervical cancer.

febit group, specialists in the field of advanced and flexible genomic analysis, today announced a strategic investment and technology development agreement with In-Q-Tel, the independent strategic investment firm that identifies innovative technology solutions to support the mission of the broader U.S. Intelligence Community.

Sequenom (NASDAQ: SQNM) today announced that it has completed the previously announced acquisition of Grand Rapids, Michigan-based Center for Molecular Medicine, a Clinical Laboratory Improvement Act (CLIA) certified clinical diagnostics laboratory. As part of the acquisition, Sequenom has formalized certain collaborative agreements with Spectrum Health and the Van Andel Research Institute, which were joint venture partners in the CLIA laboratory. The CLIA laboratory has been renamed to the Sequenom Center for Molecular Medicine (SCMM).

Nanogen, Inc. (Nasdaq: NGEN), developer of in vitro diagnostic products, has reported its unaudited financial results for the quarter ended September 30, 2008.
Revenues for the third quarter of 2008 totaled $13.8 million, representing an increase of more than 64% from the $8.4 million reported for the same quarter in 2007. Current revenue increased 7% as compared to $12.9 million in the prior quarter.

In a struggling economic environment there are a few bright spots to be found. Fluidigm Corporation is one of them. The company today announced that its third quarter product revenue tripled year-over-year, to $4.2 million, compared to $1.4 million in the third quarter of 2007.

GEN along with partner, Scintellix, and sponsor, Agilent, bring you the Microarray Challenge. Crack the code, and you can win big.

A “chip” or array that can quickly detect disorders such as Down syndrome or other diseases associated with chromosomal abnormalities proved an effective tool in prenatal diagnosis in a series of 300 cases at Baylor College of Medicine, said researchers in a report that appears in the current issue of the journal Prenatal Diagnosis.

Illumina, Inc. (NASDAQ:ILMN) today announced that the Wellcome Trust Sanger Institute has purchased 11 additional Genome Analyzers, increasing the organization’s total number of the Illumina sequencing platform to 37. The continued scale up on the Genome Analyzer will support the Sanger Institute’s many initiatives, such as its contribution to the 1000 Genome Project, which requires economical, accurate, and rapid sequence generation.

Luminex Corporation (NASDAQ: LMNX), the worldwide leader in multiplexed solutions, today announced the commercial sale and shipment of the first FLEXMAP(TM) 3D system manufactured in Austin, Texas. Full market release of the instrument is expected in the first quarter of 2009.

Illumina, Inc. (NASDAQ:ILMN) today announced that the Wellcome Trust Sanger Institute has purchased 11 additional Genome Analyzers, increasing the organization’s total number of the Illumina sequencing platform to 37. The continued scale up on the Genome Analyzer will support the Sanger Institute’s many initiatives, such as its contribution to the 1000 Genome Project, which requires economical, accurate, and rapid sequence generation.

BioReliance announces the introduction of its new protein array platform that offers greater sensitivity, reduced testing time and reliable results. The platform, brand-named ReliArray™, can simultaneously screen for four non-human pathogens in animal serum.

Affymetrix, Inc. (Nasdaq:AFFX) today announced the DMET(TM) Plus Premier Pack, the most comprehensive method for standardizing drug metabolism studies. The DMET (Drug Metabolism Enzymes and Transporters) Plus Panel features the most biologically relevant content identified by key opinion leaders from industry and academia in a cost-effective format. The DMET Plus Panel contains markers in all FDA-validated genes(1) and covers more than 90 percent of the current ADME Core markers as defined by the PharmaADME group. It offers 1,936 high-value drug metabolism and transporter markers.

Illumina, Inc. (NASDAQ:ILMN) today unveiled a new product for DNA Analysis: the Infinium(R) HD Human660W-Quad BeadChip. This four-sample BeadChip features 2.6 million genetics markers and was developed in collaboration with The Centre for Applied Genomics at the Hospital for Sick Children in Toronto, Canada and the Wellcome Trust Sanger Institute in the United Kingdom. The Human660W-Quad BeadChip builds on the content from Illumina’s HumanHap550+ BeadChip to target over 5,000 regions in the human genome known to be associated with copy number variation (CNV). First customer shipments of the Human660W-Quad are expected in December 2008.